MRNA
US EQUITY
Health Care
Biotechnology
CIK: 1682852
Moderna (MRNA) Quant Factor Diagnostic & Fair Value Model
Moderna (Ticker: MRNA) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$200.10
-1.25%
Latest Close (2026-10-23)
Market Cap: $79.89B
P/E Ratio: -
Momentum Strength
3M / 12M
+259.70%
1M: +2.71%
12M: +645.25%
Quality (ROE)
Point-in-Time
-46.27%
Trailing Return on Equity
Technical Trend
RSI 14
49.1
SMA50: $171.15
SMA200: $82.16
Valuation Multiplier
Trailing
-
Pre-Profit / Negative TTM
📊
Valuation & Multi-Factor Diagnostic
Pre-Profit / Negative TTM
MRNA has negative or near-zero trailing GAAP earnings over the trailing twelve months.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 4/9 (Moderate Financial Health)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1682852 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-07-31 | - | -$782.00M | -$1.16B | $-1.97 |
| 10-Q | 2025-12-31 | 2026-07-31 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-07-31 | - | -$825.00M | -$1.96B | $-2.13 |
| 10-Q | 2026-03-31 | 2026-05-01 | - | -$1.34B | -$630.00M | $-3.40 |
| 10-Q | 2025-03-31 | 2026-05-01 | - | -$971.00M | -$1.04B | $-2.52 |
| 10-K | 2025-12-31 | 2026-02-20 | - | -$2.82B | -$1.87B | $-7.26 |
| 10-K | 2024-12-31 | 2026-02-20 | - | -$3.56B | -$3.00B | $-9.28 |
| 10-K | 2023-12-31 | 2026-02-20 | - | -$4.71B | -$3.12B | $-12.33 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Moderna (MRNA) valuation multiples, momentum factors, and point-in-time filing conventions.
How should MRNA's current valuation multiple be interpreted? ↓
MRNA trades at a trailing P/E of -x within the Health Care sector (pre-profit / negative ttm). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are MRNA's key momentum and technical factor indicators? ↓
As of the latest close, MRNA shows a 1-month return of +2.71%, 3-month return of +259.70%, and 12-month return of +645.25%, with a 14-day RSI of 49.1. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for MRNA? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can MRNA be incorporated into systematic factor models? ↓
MRNA can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.